Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Holding ASRT?
Track your performance easily
ASRT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $1.80
Previous CloseN/A
Volume363.47K
Average Volume (3M)642.26K
Market Cap
$80.49M
Enterprise Value$73.69M
Total Cash (Recent Filing)$177.42M
Total Debt (Recent Filing)$718.78M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 05, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding95,477,800
10 Day Avg. Volume412,580
30 Day Avg. Volume642,261
Standard Deviation0.25
R-Squared0.00186
Alpha-0.00112
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.64
Price to Cash Flow (P/CF)-574.90
P/FCF Ratio27.30
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit0.59
Enterprise Value/Ebitda-4.78
Forecast
1Y Price Target
$3.03Price Target Upside278.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Assertio Therapeutics News
PremiumCompany Announcements
Assertio Therapeutics Announces Leadership Changes and Board Addition
PremiumCompany Announcements
Assertio Therapeutics Reports Strong Q3 and Board Changes
PremiumCompany Announcements
Assertio Therapeutics’ Q3 2024 Earnings OverviewBulls Say, Bears Say
Bulls Say
Financial OutlookThe company's key revenue driver, Rolvedon, is projected to generate $72M in 2025, significantly exceeding Indocin's contribution.
Market PotentialIncorporation into NCCN guidelines can potentially accelerate Rolvedon’s sales growth.
Product DifferentiationROLVEDON demonstrated unique attributes within the G-CSF drug class, emphasizing patient convenience and dosing flexibility.
Bears Say
Generic Drug ApprovalA second indomethacin generic has been approved, potentially putting further pressure on Indocin.
Legal DisputeAssertio is engaged in an ongoing dispute with Buxton Hemsley Group, Inc., and management claims Buxton’s statements are 'baseless allegations'.
Market CompetitionInability to obtain market share for products like ROLVEDON and greater-than-anticipated levels of competition.
---
Ownership Overview
2.21% Insiders
7.20% Mutual Funds
11.59% Other Institutional Investors
73.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $0.73 and its highest was $1.80 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Assertio Therapeutics Inc’s market cap is $80.49M.
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Mar 05, 2025 which is in 31 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Nov 11, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.046 by $0.016.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -0.04.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 95,477,800 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.046. Following the earnings report the stock price went down -7.609%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is Royce & Associates LLC. It holds Assertio Therapeutics Inc’s shares valued at 89K.
---
Assertio Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.03 (278.75% Upside)
$3.03 (278.75% Upside)
Blogger Sentiment
Bullish
ASRT Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $70.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.54%
12-Months-Change
Fundamentals
Return on Equity
-52.47%
Trailing 12-Months
Asset Growth
-27.37%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
ASRT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed performance with steady sales of ROLVEDON and a strong financial position offset by declining INDOCIN sales and lingering external pressures. Strategic leadership changes and exploration of new growth opportunities provide an optimistic outlook, though pricing pressures remain a concern.Read More>---
ASRT Stock 12 Month Forecast
Average Price Target
$3.03
▲(278.75% Upside)
Technical Analysis
Durect
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Eagle Pharmaceuticals
―
Xenon
―
Best Analysts Covering ASRT
1 Year
1 Year Success Rate
7/31 ratings generated profit
1 Year Average Return
-27.19%
reiterated a buy rating 3 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 22.58% of your transactions generating a profit, with an average return of -27.19% per trade.
---